NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients

NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.

Sponsor:

City of Hope Medical Center

Collaborator:

National Cancer Institute (NCI)

---

ClinicalTrials.gov Identifier: NCT05014646

Official Title: Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple Myeloma

First Posted : August 20, 2021

Click here for details on ClinicalTrials.gov

---

Drug: Cholestyramine

Drug: Leflunomide

---

Leflunomide

Leflunomide (Code C1128)

4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-

Arava

Leflunomide

LEFLUNOMIDE

leflunomide

SU101

---

Locations:

United States, California

United States, Michigan

United States, North Carolina